US 12,338,290 B2
Regimens and methods of treating multiple sclerosis using ofatumumab
Erik Wallström, Basel (CH); Marina Savelieva Praz, Binningen (CH); Algirdas Jonas Kakarieka Weisskopf, Basel (CH); and Joseph Michael Kahn, Belle Mead, NJ (US)
Assigned to Novartis AG, Basel (CH)
Filed by Novartis AG, Basel (CH)
Filed on Mar. 6, 2024, as Appl. No. 18/597,624.
Application 18/597,624 is a continuation of application No. 18/331,701, filed on Jun. 8, 2023.
Application 18/331,701 is a continuation of application No. 17/495,559, filed on Oct. 6, 2021, abandoned.
Application 17/495,559 is a continuation of application No. 16/324,619, granted, now 11,161,909, issued on Nov. 2, 2021, previously published as PCT/IB2017/054909, filed on Aug. 11, 2017.
Claims priority of provisional application 62/374,986, filed on Aug. 15, 2016.
Prior Publication US 2024/0317878 A1, Sep. 26, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 16/28 (2006.01); A61K 9/00 (2006.01); A61K 39/00 (2006.01); A61P 25/28 (2006.01); A61P 37/06 (2006.01)
CPC C07K 16/2887 (2013.01) [A61K 9/0019 (2013.01); A61P 25/28 (2018.01); A61P 37/06 (2018.01); A61K 2039/505 (2013.01); A61K 2039/54 (2013.01); A61K 2039/545 (2013.01); C07K 2317/21 (2013.01)] 18 Claims
 
1. A method of treating multiple sclerosis (MS), comprising administering a maintenance dose regimen of ofatumumab to a patient who has received a loading dose regimen, wherein:
a) the loading dose regimen comprises three once weekly 20 mg loading doses of ofatumumab; and
b) the maintenance dose regimen comprises 20 mg ofatumumab administered once monthly.